1.Development of a Standardized Suicide Prevention Program for Gatekeeper Intervention in Korea (Suicide CARE Version 2.0) to Prevent Adolescent Suicide: Version for Teachers
Hyeon-Ah LEE ; Yeon Jung LEE ; Kyong Ah KIM ; Myungjae BAIK ; Jong-Woo PAIK ; Jinmi SEOL ; Sang Min LEE ; Eun-Jin LEE ; Haewoo LEE ; Meerae LIM ; Jin Yong JUN ; Seon Wan KI ; Hong Jin JEON ; Sun Jung KWON ; Hwa-Young LEE
Psychiatry Investigation 2025;22(1):117-117
2.Changing Gadolinium-Based Contrast Agents to Prevent Recurrent Acute Adverse Drug Reactions: 6-Year Cohort Study Using Propensity Score Matching
Min Woo HAN ; Chong Hyun SUH ; Pyeong Hwa KIM ; Seonok KIM ; Ah Young KIM ; Kyung-Hyun DO ; Jeong Hyun LEE ; Dong-Il GWON ; Ah Young JUNG ; Choong Wook LEE
Korean Journal of Radiology 2025;26(2):204-204
3.Anti-inflammatory Constituents from Artemisia iwayomogi Kitamura: A Bioassay-guided Fractionation Study
Ngoc Khanh VU ; Thi Thanh LE ; Trong Trieu TRAN ; Manh Tuan HA ; Jeong Ah KIM ; Byung Sun MIN
Natural Product Sciences 2025;31(1):43-48
Bioassay-guided fractionation of the methanolic extract of Artemisia iwayomogi Kitamura led to the isolation of 12 known compounds (1‒12). Notably, this study marks the first report of 3-epimeridinol (1) being isolated and structurally characterized from a natural source. Additionally, compounds 3, 4, and 7 were isolated from the Asteraceae family for the first time. The structural elucidation of the isolated compound was achieved through analysis of 1D, 2D NMR, and MS data. Upon evaluation of their inhibitory effects against lipopolysaccharideinduced nitric oxide production, compound 12 demonstrated significant inhibitory activity with greater potency than the reference compound quercetin. These results established A. iwayomogi as a promising source of antiinflammatory agents.
4.PTP1B Inhibitory Activity of Flavonoids from the Roots of Astragalus membranaceus Bunge
Thi Ly PHAM ; Manh Tuan HA ; Byung Sun MIN ; Jeong Ah KIM
Natural Product Sciences 2025;31(1):62-73
The roots of Astragalus membranaceus Bunge have long been used in herbal medicine for their diversebiological activities. Notably, its potential anti-diabetic properties have been extensively studied, highlighting promising therapeutic prospects. In this study, we conducted a comprehensive investigation focusing on flavonoid components from the roots of A. membranaceus and their PTP1B inhibitory activity. As a result, we isolated a total of 24 flavonoids, among which formonentin (1), pratensein (3), and vesticarpan (19) emerged as the most potent inhibitors against PTP1B with IC50 value of 10.9 ± 1.09 μM, 10.0 ± 1.71 μM, and 10.3 ± 1.31 μM, respectively.Additionally, through the enzyme kinetic analysis, the inhibition mode of compound 19 was determined as a competitive inhibitor, with Ki value of 7.6 ± 1.17 μM. Furthermore, the molecular docking simulation elucidated the binding mechanism of compound 19 with PTP1B, mainly through van der Waals forces and hydrogen bonds.This study highlights the PTP1B inhibitory potential of the flavonoid constituents derived from the roots of A. membranaceus. Moreover, discovering vesticarpan (19) as a novel PTP1B inhibitor provides a significant foundation for further investigations to develop innovative therapeutic strategies for diabetes treatment.
5.Changing Gadolinium-Based Contrast Agents to Prevent Recurrent Acute Adverse Drug Reactions: 6-Year Cohort Study Using Propensity Score Matching
Min Woo HAN ; Chong Hyun SUH ; Pyeong Hwa KIM ; Seonok KIM ; Ah Young KIM ; Kyung-Hyun DO ; Jeong Hyun LEE ; Dong-Il GWON ; Ah Young JUNG ; Choong Wook LEE
Korean Journal of Radiology 2025;26(2):204-204
6.Anti-inflammatory Constituents from Artemisia iwayomogi Kitamura: A Bioassay-guided Fractionation Study
Ngoc Khanh VU ; Thi Thanh LE ; Trong Trieu TRAN ; Manh Tuan HA ; Jeong Ah KIM ; Byung Sun MIN
Natural Product Sciences 2025;31(1):43-48
Bioassay-guided fractionation of the methanolic extract of Artemisia iwayomogi Kitamura led to the isolation of 12 known compounds (1‒12). Notably, this study marks the first report of 3-epimeridinol (1) being isolated and structurally characterized from a natural source. Additionally, compounds 3, 4, and 7 were isolated from the Asteraceae family for the first time. The structural elucidation of the isolated compound was achieved through analysis of 1D, 2D NMR, and MS data. Upon evaluation of their inhibitory effects against lipopolysaccharideinduced nitric oxide production, compound 12 demonstrated significant inhibitory activity with greater potency than the reference compound quercetin. These results established A. iwayomogi as a promising source of antiinflammatory agents.
7.PTP1B Inhibitory Activity of Flavonoids from the Roots of Astragalus membranaceus Bunge
Thi Ly PHAM ; Manh Tuan HA ; Byung Sun MIN ; Jeong Ah KIM
Natural Product Sciences 2025;31(1):62-73
The roots of Astragalus membranaceus Bunge have long been used in herbal medicine for their diversebiological activities. Notably, its potential anti-diabetic properties have been extensively studied, highlighting promising therapeutic prospects. In this study, we conducted a comprehensive investigation focusing on flavonoid components from the roots of A. membranaceus and their PTP1B inhibitory activity. As a result, we isolated a total of 24 flavonoids, among which formonentin (1), pratensein (3), and vesticarpan (19) emerged as the most potent inhibitors against PTP1B with IC50 value of 10.9 ± 1.09 μM, 10.0 ± 1.71 μM, and 10.3 ± 1.31 μM, respectively.Additionally, through the enzyme kinetic analysis, the inhibition mode of compound 19 was determined as a competitive inhibitor, with Ki value of 7.6 ± 1.17 μM. Furthermore, the molecular docking simulation elucidated the binding mechanism of compound 19 with PTP1B, mainly through van der Waals forces and hydrogen bonds.This study highlights the PTP1B inhibitory potential of the flavonoid constituents derived from the roots of A. membranaceus. Moreover, discovering vesticarpan (19) as a novel PTP1B inhibitor provides a significant foundation for further investigations to develop innovative therapeutic strategies for diabetes treatment.
8.Spatiotemporal Gait Parameters During Turning and Imbalance in Parkinson’s Disease: Video-Based Analysis From a Single Camera
HoYoung JEON ; Jung Hwan SHIN ; Ri YU ; Min Kyung KANG ; Seungmin LEE ; Seoyeon KIM ; Bora JIN ; Kyung Ah WOO ; Han-Joon KIM ; Beomseok JEON
Journal of Movement Disorders 2025;18(1):87-92
Objective:
This study aims to objectively evaluate turning gait parameters in Parkinson’s disease (PD) patients using 2D-RGB video-based analysis and explore their relationships with imbalance.
Methods:
We prospectively enrolled PD patients for clinical assessment, balance analysis and gait with 180º turning. Spatiotemporal gait parameters during turning were derived using video-based analysis and correlated with modified Hoehn and Yahr (mHY) stages and center of pressure (COP) oscillations.
Results:
A total of 64 PD patients were enrolled. The PD patients with higher mHY stages (≥2.5) had significantly longer turning times, greater numbers of steps, wider step bases and less variability in step length during turns. COP oscillations were positively correlated with the mean turning time on both the anterior-posterior and right-left axes.
Conclusion
Spatiotemporal gait parameter during turning, derived from video-based gait analysis, may represent apromising biomarker for monitoring postural instability in PD patients.
9.The effects of blackcurrant extract on TNF-α-induced myotube atrophy
Ji Min KIM ; You Ree NAM ; Kyung Ah KIM
Journal of Nutrition and Health 2025;58(2):167-178
Purpose:
Skeletal muscle atrophy, characterized by a reduction in muscle mass and size, is known to be associated with inflammation and oxidative stress. This study aimed to examine the effect of blackcurrant extract on tumor necrosis factor-alpha (TNF)-α-induced myotube atrophy.
Methods:
C2C12 myotubes were treated with blackcurrant extract and cultured with TNF-α for 24 hours. The myotubes were stained using May-Grunwald Giemsa staining to measure the myotube diameter. In addition, reactive oxygen species (ROS) levels were assessed.The mRNA expression of inflammation-related markers such as interleukin (IL)-6, IL-1β, cyclooxygenase-2 (COX-2), inducible NO synthase (iNOS), as well as mitochondria dynamicsrelated markers, including mitochondrial fission protein 1 (Fis1), optic atrophy 1 (Opa1) were measured by quantitative real-time polymerase chain reaction. The expression of muscle protein degradation markers, including muscle ring finger protein 1 (MuRF-1), atrogin-1, and forkhead box protein O3 (FoXO3), as well as mitochondrial biogenesis markers such as silent information regulator T1 (Sirt1) and peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1α), were assessed by western blot analysis.
Results:
Treatment with blackcurrant extract increased the myotube diameter, which was decreased in TNF-α-induced myotube atrophy. Treatment with TNF-α increased ROS levels and the expression of MuRF-1 and atrogin-1, and these increases were significantly inhibited by treatment with the blackcurrant extract. In contrast, the phosphorylation of FoXO3 was increased by the blackcurrant extract. Furthermore, the blackcurrant extract treatment decreased the mRNA expression of IL-6, IL-1β, COX-2, and iNOS elevated by TNF-α treatment. Additionally, blackcurrant extract treatment suppressed the expression of Fis1, while increasing the expression of Opa1, Sirt1, and PGC-1α.
Conclusion
These results suggest that blackcurrant extract reduces TNF-α-induced muscle protein degradation by the enhancement of mitochondrial biogenesis and mitochondrial dynamics. Thus, this study provides foundational data supporting the potential of blackcurrant extract as a functional ingredient for the prevention of muscle atrophy.
10.Erratum to "Investigating the Immune-Stimulating Potential of β-Glucan from Aureobasidium pullulans in Cancer Immunotherapy" Biomol Ther 32(5), 556-567 (2024)
Jae-Hyeon JEONG ; Dae-Joon KIM ; Seong-Jin HONG ; Jae-Hee AHN ; Dong-Ju LEE ; Ah-Ra JANG ; Sungyun KIM ; Hyun-Jong CHO ; Jae-Young LEE ; Jong-Hwan PARK ; Young-Min KIM ; Hyun-Jeong KO
Biomolecules & Therapeutics 2025;33(1):233-233

Result Analysis
Print
Save
E-mail